A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.

A Multi-center, Study of the Non-inferiority of PedSCath Pediatric Sampling Catheter Versus a Retrospective Control Cohort Using Current Standard of Care.

This is a retrospectively-controlled clinical trial that will examine the rate of positive UTI cases among pediatrics entered into the Emergency Department and whose urine is withdrawn using the PedSCath Pediatric Sampling Catheter. The rate of postive UTI will be compared against the control population, whose urine withdrawal would have been performed with Standard of Care devices.

Study Overview

• Status: Terminated
• Conditions: Urinary Tract Infections in Children
• Intervention / Treatment: Device: PedSCath Pediatric Urinary Catheter; Device: Standard of Care

Detailed Description

This will be a multi-center, retrospective-controlled, clinical trial.

Anonymized retrospective data from two clinical sites, NewYork-Presbyterian Queens and Weill Cornell Medical College, from 2016 and 2018 will be used to define the control subject population, who were assessed for urinary tract infection (UTI) based on a urine sample taken according to Standard of Care (SoC).

Subjects entering the emergency department (ED) generally require that a urine specimen is obtained and tested to determine whether there is an active infection in the bladder. Emergency department personnel will confirm the possibility of UTI based on symptoms and inform the parents/guardians of the potential for study participation using the PedSCath. The physician will assess the subject based on Inclusion and Exclusion criteria, including non-toilet training and an upper age limit of 3 years. If determined that the subject meets inclusion/exclusion criteria, the physician will inform the parents/guardians of the subject about the study and request informed consent if the parents/guardians wish their child to participate.

Following the granting of Informed Consent, subjects will be enrolled in the study within the treatment arm and a urine sample of 2-3 ml will be taken via the PedSCath. All study assessments, from enrollment through urine sample collection, will occur over a single visit to the ED. Per standard of care, any treatment following the diagnosis will be performed by hospital staff based on physician assessment. Up to 3 run-in subjects per PedSCath user will be treated with PedSCath to allow PedSCath users to become familiar with PedSCath mechanism.

• Study Type: Observational
• Enrollment (Actual): 2

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 11355
      • NewYork-Presbyterian Queens

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 3 years (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Prospective cohort subjects will enter the emergency department presenting symptoms of UTI. The Control group will be retrospectively enrolled by gathering data through anonymized 2016 and 2018 subject data gathered from the study's clinical sites.

Description

Inclusion Criteria:

• Subject is 3 years of age or younger.
• Subject is non-toilet trained, as communicated by subject's parent/guardian.
• Subject is presenting to the emergency department with symptoms for UTI, as described by AAP guidelines (Newborns with UTI may present with jaundice, sepsis, failure to thrive, vomiting, or fever. In infants and young children, typical signs and symptoms include fever, strong-smelling urine, hematuria, abdominal or flank pain, and new-onset urinary incontinence) or as determined by PI.
• Subject's parent/guardian is able to provide informed consent.

Exclusion Criteria:

• Any subject with known underlying abnormalities to the genitourinary tract (e.g. prenatal hydronephrosis).
• Any subject who has had prior genitourinary tract or abdominal surgery.
• Any subject who is toilet trained (i.e. able to provide a clean catch urine sample).
• Any subject with an active rash or skin lesion in the suprapubic area.
• Any subject with a known allergy to LDPE, Elvax, or Crodamide plastics.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PedSCath; Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.	Device: PedSCath Pediatric Urinary Catheter; PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.; Other Names: Wiygul Catheter
Retrospective Control; Generated from 2016 and 2018 anonymized subject data from the clinical sites.	Device: Standard of Care; Current Standard of Care for pediatric patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The primary effectiveness endpoint is the proportion of PedSCath subjects with positive UTI diagnosis versus that of Control subjects.	The primary effectiveness endpoint is the proportion of PedSCath subjects with positive UTI diagnosis versus that of Control subjects. The objective is to demonstrate a lower rate of positive urinalysis/urine culture results in the PedSCath cohort.	Through study completion, an estimation of 1 year.

Collaborators and Investigators

• Sponsor: Big Blue Biotech, Inc.
• Investigators: Study Chair: Evan M Haynes, MA, Big Blue Biotech, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): August 27, 2021
• Primary Completion (Actual): February 2, 2023
• Study Completion (Actual): February 2, 2023

Study Registration Dates

• First Submitted: December 2, 2020
• First Submitted That Met QC Criteria: February 17, 2021
• First Posted (Actual): February 21, 2021

Study Record Updates

• Last Update Posted (Actual): June 22, 2023
• Last Update Submitted That Met QC Criteria: June 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urinary Tract Infections
• Other Study ID Numbers: BBBInc: 0619

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No